2026 payer coverage update — GLP-1 formulary changes by insurer
Posting this as an important update for the insurance & access community. Please read carefully as this may affect your current plans.
I will keep this thread updated as new information becomes available. If you have additional information or corrections, please post below and I will incorporate confirmed updates into this OP.
Key points:
Bookmarking this thread is recommended — it will be updated as the situation evolves.
InsuranceTom said:2026 payer coverage update — GLP-1 formulary changes by insurer Posting this as an important update for the insurance & access community.
Agreed, and coverage criteria are plan-specific rather than insurer-specific. Two people with the same insurer and different employers have different rules, which is why "my insurer covers it" is not transferable information.
InsuranceTom said:2026 payer coverage update — GLP-1 formulary changes by insurer Posting this as an important update for the insurance & access community.
I read this differently from InsuranceTom, on substance rather than tone. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemTaking the question as asked, rather than the general version of it. Denials are usually procedural rather than clinical, and the order that works reflects that. Get the denial reason in writing, because it names the criterion you failed. Then supply the documentation that criterion asks for — usually documented BMI with a comorbidity, or a failed prior therapy. Then appeal, and ask for a peer-to-peer review, because a prescriber talking to a reviewing clinician resolves a large fraction of denials that written appeals do not. Manufacturer copay assistance is separate and applies mainly to commercial insurance, and patient assistance programmes are means-tested rather than a discount.
TrialNerd_Beth said:Agreed, and coverage criteria are plan-specific rather than insurer-specific.
Same experience, arrived at from the opposite direction. Nothing to add that would improve it.